Light Em UP! Targeted Combination Therapy Kills Cancer Cells in Less than 2 Hours
Show Guests: Matthew Gdovin & Tom Roberts, CEO
According the National Cancer Society, a staggering 606,000 people died of cancer in the U.S in 2019. When a cancer tumor grows in the body, it creates an acidic environment on the outside of its cells. This acidic environment causes blood vessels to grow and attach to the tumor in an attempt to remove the acid. In something of a biological trick, the tumor then commandeers the blood vessels and uses them as a source of nutrients to help it grow. The current standard of care to treat cancer is to cut (surgery), poison (chemotherapy), or ablate (radiation therapy). Unfortunately, these treatments can cause debilitating unwanted side-effects.
Vitanova Biomedical (VNB) is developing an alternative therapy, Light-Activated Acidosis (LAIA), which uses a focused beam of light to activate a targeted drug injected into the tumor. Once activated, this drug causes the cancer cell to become very acid on the inside triggering rapid apoptosis (cell death). LAIA therapy has proven capable of killing up to 95 percent of cancer cells within two hours across five different cancer cell types including breast cancers including the very aggressive triple negative breast cancer (MDA-MB-231), two types of prostate cancers (LNCaP and 22RV1), and a pancreatic cancer (BxPC3). sparing near-by healthy tissue, and potentially causes no debilitating unwanted side effects.
Tom Roberts, the company’s CEO, resports that VNB has entered a global strategic partnership with LiteCure Medical Lasers, and was awarded a competitive National Science Foundation SBIR Program Phase I grant to further develop LAIA therapy. Together, these partnerships should help to advance VNB’s LAIA therapy from laboratory bench to an FDA submission….and ultimately provide an effective alternative cancer treatment for multiple cancer types.